# Gilead Sciences

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/gilead-sciences
Canonical HTML page: https://getbiobrief.com/entity/gilead-sciences

## Timeline

- **2026-03-17**: New Limits Reported — States begin implementing restrictive eligibility and waitlists for drug assistance programs.
- **2024**: Fiscal Pressure Mounts — Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
- **2011**: Waitlist Peak — National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
- **1990**: Ryan White CARE Act — Federal legislation established to provide a safety net for HIV/AIDS care and treatment.

## Recent coverage (2 stories)

### State Budget Cuts Force New Restrictions on HIV Drug Assistance Programs
2026-03-17 21:17:57 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
Full story: https://getbiobrief.com/story/hiv-drug-assistance-program-limits-2026

### Florida Restores Critical Funding to AIDS Drug Assistance Program
2026-03-13 01:37:34 · Sentiment: Positive · Impact: 6/10 · Sources: 2

The Florida Legislature has approved a stopgap bill to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis in medication access. This legislative action ensures that thousands of low-income residents living with HIV/AIDS will continue to receive life-saving antiretroviral treatments without interruption.
Full story: https://getbiobrief.com/story/florida-restores-adap-funding-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.